A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
Stopped This protocol was terminated not for safety reasons, but because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG: Inhaled Human Insulin (Exubera)
- DRUG: Inhaled Human Insulin (Exubera)
Sponsor
Pfizer